Hepatitis B, Acute

2023 Case Definition

CSTE Position Statement Number: 23-ID-05

A1. Clinical Criteria

*Alternative diagnoses may include evidence of acute liver disease due to other causes or advanced liver disease due to hepatitis B reactivation (see section VIB), pre-existing chronic HBV infection, other causes including alcohol exposure, other viral hepatitis, hemochromatosis, or conditions known to produce false positives of hepatitis B surface antigen, etc.

A2. Laboratory Criteria**

Confirmatory Laboratory Evidence:

Acute HBV Infection:

Tier 1

Tier 2

Presumptive Laboratory Evidence:

Acute HBV Infection:

**Note: The categorical labels used here to stratify laboratory evidence are intended to support the standardization of case classifications for public health surveillance. The categorical labels should not be used to interpret the utility or validity of any laboratory test methodology.
If information on HBsAg test method is available and HBsAg confirmatory neutralization was performed as recommended, HBsAg positive by confirmatory neutralization.
†† DNA detection by nucleic acid test, including qualitative, quantitative, or genotype testing.

A3. Epidemiologic Linkage Criteria

N/A

A4. Case Classifications***

Confirmed:

Acute HBV Infection

Probable:

Acute HBV Infection

***Individuals born in the US, under or equal to the age of 24 months, and born to a mother with documented evidence of hepatitis B infection should be reporting using the Perinatal Hepatitis B Position Statement (16-ID-06), unless there is evidence that exposure occurred via a non-perinatal mechanism (e.g., healthcare acquired).

B. Criteria to Distinguish a New Case of Acute or Chronic Hepatitis B from Reports or Notifications which Should Not be Enumerated as a New Case for Surveillance

Date Posted: